Trials / Unknown
UnknownNCT00870402
Aldosterone in Diabetic Nephropathy
Effect of Aldosterone Antagonism in the Reduction of Albuminuria and Diastolic Disfunction of Patients With Diabetic Nephropathy.
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 160 (estimated)
- Sponsor
- Universidad de los Andes, Chile · Academic / Other
- Sex
- All
- Age
- 30 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether spironolactone are effective in the reduction of albuminuria and diastolic disfunction of subjects with diabetic nephropathy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Spironolactone | 25 mg per day for 9 months |
| DRUG | Placebo | Placebo 1 tablet per day for nine months |
Timeline
- Start date
- 2009-03-01
- Primary completion
- 2009-12-01
- Completion
- 2010-03-01
- First posted
- 2009-03-27
- Last updated
- 2009-03-27
Locations
1 site across 1 country: Chile
Source: ClinicalTrials.gov record NCT00870402. Inclusion in this directory is not an endorsement.